Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status.
Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status.
复制标题
尿可溶性 CD163 水平可预测 IgA 肾病缓解状态
DOI：
10.3389/fimmu.2021.769802
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Liu H
中科院分区：
文献类型：
--
作者：
Gong S;Jin S;Li Y;Jiang W;Zhang Z;Shen Z;Wang J;Zhou H;Liu X;Xu X;Ding X;Shi Y;Liu H
需要疾病活动的非侵入性生物标志物来预测伊加肾病（IgAN）患者的疾病缓解状态。可溶性CD 163（sCD 163），由单核细胞和巨噬细胞脱落，是与巨噬细胞过度活化相关疾病的潜在生物标志物。我们研究了349例经活检诊断的IgA肾病患者尿sCD 163（u-sCD 163）与组织病理学活动和临床表现的关系。通过酶联免疫吸附试验测定U-sCD 163。在IgAN患者中，较高的u-sCD 163水平与更严重的组织学病变、更多的蛋白尿和更差的肾功能相关。此外，u-sCD 163与肾小管间质CD 163+巨噬细胞浸润相关。在校正分析中，高u-sCD 163水平（>3.57 ng/mg Cr）与IgAN缓解失败风险增加2.66倍相关。将u-sCD 163水平添加到包含活检时的临床数据和MEST-C评分的模型中显著改善了IgAN缓解状态的风险预测（AUC 0.788）。总之，我们的研究结果表明，u-sCD 163可能是一个有用的非侵入性生物标志物，以评估疾病的严重程度和IgAN的缓解状态。
Noninvasive biomarkers of disease activity are needed to predict disease remission status in patients with IgA nephropathy (IgAN). Soluble CD163 (sCD163), shed by monocytes and macrophages, is a potential biomarker in diseases associated with excessive macrophage activation. We investigated the association of urinary sCD163 (u-sCD163) with histopathological activity and clinical manifestations in 349 patients with biopsy-diagnosed IgAN. U-sCD163 was measured via enzyme-linked immunosorbent assay. In patients with IgAN, higher u-sCD163 levels were associated with histological lesions of greater severity, as well as more proteinuria and poorer renal function. Additionally, u-sCD163 was correlated with infiltration of tubulointerstitial CD163+ macrophages. High u-sCD163 levels (>3.57 ng/mg Cr) were associated with a 2.66-fold greater risk for IgAN remission failure in adjusted analyses. Adding u-sCD163 levels to the model containing clinical data at biopsy and MEST-C score significantly improved the risk prediction of IgAN remission status (AUC 0.788). Together, our results suggest that u-sCD163 may be a useful noninvasive biomarker to evaluate disease severity and remission status of IgAN.